Trials / Active Not Recruiting
Active Not RecruitingNCT06487156
A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
FINN (First-line Ipilimumab + Nivolumab in NSCLC): An Italy, Nationwide, Prospective, Observational, Multicenter Study in Patients With First-line Nivolumab Plus Ipilimumab Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 404 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of first-line nivolumab plus ipilimumab treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) in Italy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab + ipilimumab | As per product label |
Timeline
- Start date
- 2023-10-11
- Primary completion
- 2030-10-11
- Completion
- 2030-10-11
- First posted
- 2024-07-05
- Last updated
- 2026-01-27
Locations
1 site across 1 country: Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06487156. Inclusion in this directory is not an endorsement.